BriaCell Reports Prelim Disease Control Rate Of 61% In Evaluable Phase 2 Advanced Breast Cancer Patients Treated With Briacell's Bria-imt Regimen; Control Rate Of 50% Reported In Evaluable Patients Who Failed Prior ADC Therapy
Portfolio Pulse from Benzinga Newsdesk
BriaCell announced a 61% disease control rate in Phase 2 advanced breast cancer patients treated with Bria-IMT regimen, and a 50% control rate in those who failed prior ADC therapy. A notable responder with metastatic liver tumor showed significant improvement after failing 4 prior therapies.
February 07, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BriaCell's Bria-IMT regimen reports a 61% disease control rate in Phase 2 breast cancer study, with a 50% rate in patients failing prior ADC therapy.
The positive results from the Phase 2 study of Bria-IMT in treating advanced breast cancer, especially in patients who have failed prior ADC therapy, indicate a strong potential for BriaCell's treatment regimen. This could lead to increased investor confidence and potentially higher demand for BCTX shares in the short term. The significant improvement in a notable responder further underscores the potential efficacy of the treatment, which could positively impact BCTX's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100